4.4 Review

Potential Therapeutic Agents Against Par-4 Target for Cancer Treatment: Where are we Going?

Journal

CURRENT DRUG TARGETS
Volume 20, Issue 6, Pages 635-654

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1389450120666181126122440

Keywords

Prostate apoptosis response-4; therapeutic innovation; tumor suppressor protein; therapeutic target; therapeutic protein; Par-4 localization

Funding

  1. Federal University of Pernambuco, Fundacao de Amparo a Ciencia e Tecnologia do Estado de Pernambuco (Facepe) Instituto de Ciencia e Tecnologia para Inovacao Farmaceutica (INCT_if)
  2. Coordenacao de Aperfeicoamento de pessoal de Nivel Superior (CAPES)

Ask authors/readers for more resources

One of the greatest challenges of cancer therapeutics nowadays is to find selective targets successfully. Prostate apoptosis response-4 (Par-4) is a selective tumor suppressor protein with an interesting therapeutic potential due to its specificity on inducing apoptosis in cancer cells. Par-4 activity and levels can be downregulated in several tumors and cancer cell types, indicating poor prognosis and treatment resistance. Efforts to increase Par-4 expression levels have been studied, including its use as a therapeutic protein by transfection with adenoviral vectors or plasmids. However, gene therapy is very complex and still presents many hurdles to be overcome. We decided to review molecules and drugs with the capacity to upregulate Par-4 and, thereby, be an alternative to reach this druggable target. In addition, Par-4 localization and function are reviewed in some cancers, clarifying how it can be used as a therapeutic target.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available